KRAS was the most altered gene in this study and is now an actionable alteration for most patients with PDAC through clinical trials.28 Our study demonstrates that tissue NGS can identify slightly more KRAS alterations than ctDNA; this can be related to the level of tumor burden and variability in the shedding of the cancer cells. This evidence concerns the gene KRAS and neoplasm.